Corcept Therapeutics

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Corcept Therapeutics reports robust earnings, navigates legal challenges for growth

Corcept Therapeutics demonstrated strong financial performance, stability, and strategic investments in key areas of its business.
While facing legal challenges and adapting to industry changes, the company capitalized on opportunities for growth and innovation.
Overall, Corcept's focus on clinical advancements and strategic investments positions it well for future success and expansion in the healthcare sector.

Corcept Therapeutics reports revenue growth, legal battles with Teva

Corcept Therapeutics delivered strong Q1 performance with revenue growth and a robust financial position.
The company faces challenges in managing expenses, legal battles, and sustaining R&D investments.
Opportunities lie in sales force expansion, clinical trials, and upcoming studies for growth and innovation.
Overall, Corcept's strategic focus on growth and legal defense positions it for future success in the market.

Corcept Therapeutics reports robust Q2 earnings and expands treatment reach

Corcept Therapeutics delivered strong financial performance, raised revenue guidance, and showcased progress in clinical development programs.
While facing legal challenges and market expansion complexities, the company's proactive strategies and positive trial results position it well for future growth.
Opportunities in partnerships, physician engagement, and broadening disease applications underscore Corcept's potential for continued success and impact in the healthcare industry.

Corcept Therapeutics excels in Q3, eyes growth in new markets

Corcept Therapeutics demonstrated robust financials, strategic wins in legal battles, and a focus on market expansion and product innovation.
While facing challenges in maintaining competitive positioning and navigating regulatory landscapes, the company is poised for growth.
With a strong performance in Q3 2023 and promising opportunities ahead, Corcept is well-positioned to capitalize on its strengths and drive future success.

Corcept Therapeutics reports robust Q4 revenue and diversifies pipeline

Corcept Therapeutics demonstrated strong financial performance in Q4 2023 with revenue growth and profitability.
The company's ongoing research and diversified pipeline position it well for future growth.
Challenges include legal disputes and market competition, but strategic planning and label expansions offer opportunities.
Overall, Corcept's financial stability, confidence in growth, and focus on treatment efficacy are key takeaways.

Corcept Therapeutics reports robust Q1 performance and eyes market expansion

Corcept Therapeutics delivered strong financial performance in Q1 2024, with revenue growth, increased net income, and raised revenue guidance.
The company's focus on innovative treatments for hypercortisolism and various cancers positions it well for future growth and market expansion.
While facing challenges like legal battles and operational complexity, Corcept remains optimistic about its pipeline and market potential.

Corcept Therapeutics reports strong Q2 performance amidst pipeline advancements

Corcept Therapeutics demonstrated robust financial performance and commercial growth in Q2 2024, supported by a strong cash position.
The company's pipeline strength was evident through positive study results for relacorilant and ongoing trials in various medical conditions.
While facing legal challenges and NDA submission delays, Corcept has opportunities to leverage its pipeline and market strategies for future success.

Corcept Therapeutics reports strong Q3 earnings and advances pipeline

Corcept Therapeutics delivered robust financial results, showing substantial revenue growth and profitability in Q3 2024. The company's pipeline progress and expanded revenue guidance underscore its strong market position and growth potential.
While facing legal challenges and complexities in clinical development, Corcept's strategic initiatives in multiple therapeutic areas and combination therapies position it well to capitalize on market opportunities and drive future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company. It engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Corcept (CORT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's Why Momentum in Corcept (CORT) Should Keep going

Truist Securities raised the price target for Corcept Therapeutics Incorporated CORT and cites continued momentum in Korlym sales more than a decade after launch amid increasing competition and says it “is impressive and difficult to ignore.”

Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast

Aurinia Pharmaceuticals

Viridian Therapeutics

Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the 'Big Mo,' indicating strong momentum that could lead to additional upward movement. We follow up on these three small biotech/biopharma names and bring followers up to date on the recent positive news flow around them in the paragraphs below.

3 Small Biotech Stocks With The 'Big Mo' Right Now

Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Corcept (CORT) Moves 6.5% Higher: Will This Strength Last?

Corcept is a profitable midcap biotechnology company specializing in treating Cushing's Syndrome, with significant potential for revenue growth and expansion into other therapeutic areas. Recent study suggests Cushing's Syndrome is more prevalent than believed, leading to a significant expansion of its potential patient base. Corcept has developed Relacorilant as a far safer and more effective drug than its current drug Korlym for Cushing's which has just gone generic.

Corcept Therapeutics - Three Dynamic Catalysts To Reaccelerate Growth

CORT's Cushing's syndrome drug, Korlym, has been performing well. The NDA for lead candidate, relacorilant, in Cushing's syndrome will be filed shortly.

Corcept Shares Rise More Than 45% in Six Months: Here's Why

Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Corcept (CORT) Upgraded to Buy: Here's Why

NEW YORK , Aug. 26, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Corcept Therapeutics Incorporated (NASDAQ: CORT) on behalf of the company's shareholders.  The investigation seeks to determine whether Corcept's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT)

The consensus price target hints at a 70.6% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Corcept (CORT) Could Rally 70.58%: Here's is How to Trade

Akebia Therapeutics

Amneal Pharmaceuticals

Bioventus

Foghorn Therapeutics

Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.

5 Small Drug Stocks to Buy as Innovation Reaches Peak

Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run?

Corcept (CORT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Can Corcept (CORT) Run Higher on Rising Earnings Estimates?

Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice

The consensus price target hints at a 37.6% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 37.6% Upside in Corcept (CORT): Can the Stock Really Move This High?

Corcept Therapeutics' strong Q2 earnings exceed expectations, with revenue climbing 39% YoY and EPS beating analyst estimates. The District Court ruled in favor of Teva, enabling the launch of a generic Korlym, which threatens Corcept's revenue. Corcept faces a lawsuit accusing it of antitrust behavior and alleged illicit bribes.

Corcept Therapeutics: Q2 Gains Overshadowed By Generic Competition And Speculative Pipeline

Corcept (CORT) beats on both earnings and sales in the second quarter of 2024. The company increases revenue guidance for 2024.

Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates

Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q2 2024 Earnings Conference Call July 29, 2024 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charles Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer, President and Director Sean Maduck - President of Endocrinology William Guyer - Chief Development Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann & Co. David Amsellem - Piper Sandler & Co. Swayampakula Ramakanth - H.C. Wainwright Joon Lee - Truist Operator Hello.

Corcept Therapeutics Incorporated (CORT) Q2 2024 Earnings Call Transcript

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.25 per share a year ago.

Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates

MENLO PARK, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

Calix

CarGurus

Catalyst Pharmaceuticals

Gogo

Moelis

MYR Group

Palomar

Shutterstock

StepStone Group

After years of dominance by the largest tech companies in the U.S. stock market, interest is spreading to overlooked companies that might be a better value for investors looking to diversify, lower their risk or do some bargain shopping.

These small-cap stocks score highest when screened for quality

Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

What Makes Corcept (CORT) a Good Fit for 'Trend Investing'

AstraZeneca

Boston Scientific

Crinetics Pharmaceuticals Inc

Cytokinetics

Jazz Pharmaceuticals

Zoetis

While innovations such as artificial intelligence have become all the rage, there's another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if you haven't considered the sector, it's really time to focus on biotech stocks.

7 Biotech Stocks to Boost Your Portfolio to Peak Health

Corcept's (CORT) pipeline progress has been encouraging with relacorilant currently under evaluation for Cushing's syndrome. The NDA for relacorilant is expected to be filed in the third quarter.

Corcept (CORT) Shares Rise 20% in Three Months: Here's Why

VanEck Vectors Biotech ETF

Royalty Pharma

I'm on the hunt for ‘Strong Buy' biotech stocks.  According to Finviz.com, there are 680 U.S.-listed biotech stocks.

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024

MENLO PARK, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that results from the prevalence phase of its CATALYST study of hypercortisolism (Cushing's syndrome) in patients with difficult-to-control type 2 diabetes were presented at the American Diabetes Association's 84th Scientific Sessions.

News for Corcept Therapeutics Stock (CORT)